To read the full story
Related Article
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
- Astellas’ 9-Month Sales Dip 1.6%, but in Positive Territory If Forex Impact Excluded
February 3, 2020
- Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
- Astellas Secures Q1 Growth as Xtandi, Betanis Offset LOE Impact
July 31, 2019
- Astellas Looks to Fortify China Biz via Global Commercial Rejig
April 26, 2019
- Astellas Sales Up 1.1% Driven by Xtandi, OAB Drugs, despite Slump in Japan Business
November 1, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
BUSINESS
- Shionogi, Cilcare Ink Research Collab on Novel Hearing Loss Drugs
May 12, 2025
- Canaglu Now Available in Thailand: Mitsubishi Tanabe
May 12, 2025
- Keytruda Tops Japan Drug Sales Ranking for 19th Month: Encise
May 12, 2025
- Japan Ethical Drug Sales Up 5.2% in March: Crecon
May 12, 2025
- Otsuka, Keio Join Hands to Facilitate “Social Implementation” of Psychedelics
May 12, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…